江苏康缘药业股份有限公司关于实际控制人、董事增持公司股份的公告
Filed with SSE ·
On 6ix: 6ix.com/news/news-16
6ix hasn’t read this filing yet.
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Announcement on Shareholding Increase by Persons Acting in Concert of Actual Controllers
- Announcement on Voluntary Shareholding Increase Plan by Certain Directors and Senior Management Members
- Report for Q3 2025
- Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice
- Announcement on Pledge of Some Shares Held by Shareholders with Over 5% Shares
Later from Jiangsu Kanion Pharmaceutical
- Announcement on the Inclusion of the Company’s Partial Drugs in the National Medical Insurance Catalog
- Announcement on Shareholding Increase Result of Some Directors and Senior Management Members
- Announcement on Cancelling the Board of Supervisors and Amending the Articles of Association and Some Governance Systems
- Announcement on Obtaining the Drug Registration Certificate for Xiebai San Granules
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical